These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27748322)

  • 1. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori.
    Kekilli M; Onal IK; Ocal S; Dogan Z; Tanoglu A
    Saudi J Gastroenterol; 2016; 22(5):366-369. PubMed ID: 27748322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
    Kahramanoğlu Aksoy E; Pirinçci Sapmaz F; Göktaş Z; Uzman M; Nazlıgül Y
    Med Princ Pract; 2017; 26(6):523-529. PubMed ID: 29131124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection.
    Demirci H; Uygun İlikhan S; Öztürk K; Üstündağ Y; Kurt Ö; Bilici M; Köktürk F; Uygun A
    Turk J Gastroenterol; 2015 Nov; 26(6):456-60. PubMed ID: 26510082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.
    Choi J; Jang JY; Kim JS; Park HY; Choe YH; Kim KM
    J Korean Med Sci; 2006 Dec; 21(6):1037-40. PubMed ID: 17179683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
    Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
    Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
    Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
    Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B; Wang J; Li J; Liu L; Chen Y
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
    Kadayifci A; Uygun A; Polat Z; Kantarcioğlu M; Kılcıler G; Başer O; Ozcan A; Emer O
    Turk J Gastroenterol; 2012 Feb; 23(1):8-13. PubMed ID: 22505373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
    Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
    Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
    Lo WC; Lin HJ; Wang K; Perng CL; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Mar; 59(3):171-6. PubMed ID: 9198292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.